microdosing glp 1 for menopause GLP-1 Perimenopause and Menopause: A Hormone-Aware Metabolic Framework Exploring Microdosing GLP-1 Medications: Benefits

Description

The drugs are part of a broader class of medicine known as GLP-1s that have grown wildly popular for everything from type 2 diabetes to weight loss and are increasingly seen as having potential benefits far beyond those two conditions

Its fast onboarding, transparent pricing, and all-digital experience make it appealing to anyone who values convenience and control

When you stop a GLP-1, the medication leaves your system gradually over several weeks

this dose is for tolerance, not efficacy Drug levels building but not yet at steady state Week 4-8: First Dose Increase (4mg) Appetite suppression becomes more pronounced Weight loss begins (typically 2-5 lbs in this period) GI side effects may briefly worsen then stabilize Reaching ~90% of steady state for current dose Week 12-16: Therapeutic Range (8mg) Significant appetite suppression and satiety Weight loss accelerates (4-8 lbs expected in this phase) Energy expenditure increase may become noticeable (feeling warmer, higher resting heart rate) Many users find this dose sufficient and don't escalate further Week 20-24: Maximum Dose (12mg, if needed) Peak therapeutic effect for those who escalate to maximum dose Cumulative weight loss typically 15-20% by this point Side effects usually stabilized if titration was gradual Full steady-state levels reached (~4-5 weeks at this dose) Week 24-48: Maintenance Phase Continued weight loss at a slower rate (1-2 lbs per week) Approaching maximum weight loss (~24% at 12mg dose) Metabolic improvements (BP, lipids, glucose) become more pronounced Side effects minimal as body fully adapted Pharmacokinetics matter: Retatrutide has a half-life of approximately 6 days, which means it takes about 4-5 weeks (4-5 half-lives) to reach steady-state drug levels at each dose